Rituximab Treatment for Idiopathic Hypertrophic Pachymeningitis.
10.3988/jcn.2017.13.2.155
- Author:
Yoonhyuk JANG
1
;
Soon Tae LEE
;
Keun Hwa JUNG
;
Kon CHU
;
Sang Kun LEE
Author Information
1. Department of Neurology, Seoul National University Hospital, Seoul, Korea. slee@snuh.org
- Publication Type:Original Article
- Keywords:
idiopathic hypertrophic pachymeningitis;
rituximab;
steroid-refractory hypertrophic pachymeningitis
- MeSH:
Autoimmunity;
Cohort Studies;
Cranial Nerve Diseases;
Headache;
Humans;
Magnetic Resonance Imaging;
Meningitis*;
Neurologic Manifestations;
Paresthesia;
Rare Diseases;
Recurrence;
Rituximab*;
Seizures;
Steroids
- From:Journal of Clinical Neurology
2017;13(2):155-161
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND PURPOSE: Hypertrophic pachymeningitis (HP) is a rare disease caused by autoimmunity in the meninx that causes various neurologic symptoms, including headache, seizures, weakness, paresthesia, and cranial nerve palsies. Although the first-line therapy for HP is steroids, many HP cases are refractory to steroids or recur when the steroids are tapered. Here we report three HP cases that were successfully treated with rituximab (RTX). METHODS: From an institutional cohort recruited from April 2012 to July 2016, three HP cases that were identified to be steroid-refractory were treated with RTX (four weekly doses of 375 mg/m²). Clinical improvement was assessed by the number of relapses of any neurologic symptom and the largest dural thickness in MRI. RESULTS: All three patients were recurrence-free of neurologic symptoms and exhibited prominent decreases in the dural thickness after RTX treatment. No adverse events were observed in the patients. CONCLUSIONS: We suggest RTX as a second-line therapy for steroid-refractory HP. Further studies are warranted to confirm this observation in a larger population and to consider RTX as a first-line therapy.
